CN103249420A - 口服用皮肤性状改善剂 - Google Patents
口服用皮肤性状改善剂 Download PDFInfo
- Publication number
- CN103249420A CN103249420A CN2011800317425A CN201180031742A CN103249420A CN 103249420 A CN103249420 A CN 103249420A CN 2011800317425 A CN2011800317425 A CN 2011800317425A CN 201180031742 A CN201180031742 A CN 201180031742A CN 103249420 A CN103249420 A CN 103249420A
- Authority
- CN
- China
- Prior art keywords
- skin
- bifidobacterium
- streptococcus
- ferm
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 26
- 241000194017 Streptococcus Species 0.000 claims abstract description 18
- 235000013336 milk Nutrition 0.000 claims description 91
- 210000004080 milk Anatomy 0.000 claims description 91
- 239000008267 milk Substances 0.000 claims description 85
- 241000186012 Bifidobacterium breve Species 0.000 claims description 48
- 238000000855 fermentation Methods 0.000 claims description 48
- 230000004151 fermentation Effects 0.000 claims description 48
- 230000000844 anti-bacterial effect Effects 0.000 claims description 37
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- 230000009467 reduction Effects 0.000 claims description 19
- 230000005855 radiation Effects 0.000 claims description 18
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 230000001976 improved effect Effects 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 10
- 229930182830 galactose Natural products 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000000630 rising effect Effects 0.000 claims 3
- 241000894006 Bacteria Species 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 31
- 235000015140 cultured milk Nutrition 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 60
- 239000000047 product Substances 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 230000035622 drinking Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 238000004321 preservation Methods 0.000 description 14
- 235000020183 skimmed milk Nutrition 0.000 description 14
- 239000006188 syrup Substances 0.000 description 14
- 235000020357 syrup Nutrition 0.000 description 14
- 235000013305 food Nutrition 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 229940039696 lactobacillus Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000012531 culture fluid Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 240000001929 Lactobacillus brevis Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 229940124587 cephalosporin Drugs 0.000 description 6
- 150000001780 cephalosporins Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- 102000004172 Cathepsin L Human genes 0.000 description 4
- 108090000624 Cathepsin L Proteins 0.000 description 4
- 229920000832 Cutin Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 210000000736 corneocyte Anatomy 0.000 description 4
- -1 fatty acid esters Chemical class 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 3
- 241000194048 Streptococcus equi Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 2
- 241000186160 Bifidobacterium pseudolongum subsp. globosum Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186842 Lactobacillus coryniformis Species 0.000 description 2
- 241001134659 Lactobacillus curvatus Species 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241001468191 Lactobacillus kefiri Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000186684 Lactobacillus pentosus Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 2
- 241000194038 Lactococcus plantarum Species 0.000 description 2
- 241000192129 Leuconostoc lactis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000191998 Pediococcus acidilactici Species 0.000 description 2
- 241000191996 Pediococcus pentosaceus Species 0.000 description 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000500332 Tetragenococcus halophilus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241001495388 Bifidobacterium choerinum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186147 Bifidobacterium longum subsp. suis Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241000186851 Lactobacillus mali Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 244000172809 Leuconostoc cremoris Species 0.000 description 1
- 235000017632 Leuconostoc cremoris Nutrition 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 1
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- QALAKUHQOSUJEU-UHFFFAOYSA-N calcium;magnesium Chemical compound [Mg+2].[Ca+2] QALAKUHQOSUJEU-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JFTBTTPUYRGXDG-UHFFFAOYSA-N methyl violet Chemical compound Cl.C1=CC(=NC)C=CC1=C(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 JFTBTTPUYRGXDG-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000010729 system oil Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Dairy Products (AREA)
Abstract
本发明提供口服摄取的发挥优异效果的皮肤性状改善剂。该口服用皮肤性状改善剂,以链球菌属细菌和双歧杆菌属细菌、或含有该2种细菌的发酵乳作为有效成分。
Description
技术领域
本发明涉及通过口服摄取改善角质水分含量等的皮肤性状的皮肤性状改善剂。
背景技术
皮肤由于暴露于紫外线而引起炎症、免疫抑制、氧化、DNA损伤等,其结果发生水分量降低、皱纹形成、弹力性降低、皮肤的老化促进等。对于这些皮肤性状的恶化,通常以外用剂的形态投与保湿剂、其他成分。
与此相对,近年来,通过口服摄取保湿成分或抗炎症成分等来改善皮肤性状的方法也有报告(专利文献1、2)。并且,分别报告有嗜热链球菌抑制特应性皮炎(专利文献3)和双歧杆菌属细菌改善皮肤的厚度、弹力性的降低(专利文献4)。
现有技术文献
专利文献
专利文献1:日本特开2001-252048号公报
专利文献2:日本特开2005-206578号公报
专利文献3:日本特开2007-39423号公报
专利文献4:日本特开2010-6757号公报
发明内容
发明所要解决的课题
但是,现有的口服用皮肤性状改善剂,其效果不充分,期望具有更优异的皮肤性状改善效果的材料。
因此,本发明的课题在于提供一种口服摄取的发挥优异效果的皮肤性状改善剂。
用于解决课题的方法
在此,本发明的发明者口服投与各种乳酸菌群和使用其的发酵乳,研究对于通过紫外线照射引起的皮肤问题的作用,结果发现如果并用嗜热链球菌属细菌和双歧杆菌属细菌,能够协同增强各自的皮肤性状改善效果,得到优异的口服投与用皮肤性状改善剂,从而完成了本发明。
即,本发明提供以链球菌属细菌和双歧杆菌属细菌、或含有该2种细菌的发酵乳作为有效成分的口服用皮肤性状改善剂。
此外,本发明提供用于口服摄取改善皮肤性状的链球菌属细菌和双歧杆菌属细菌的组合、或含有该2种细菌的发酵乳。
并且,本发明提供皮肤性状的改善方法,其特征在于,口服摄取链球菌属细菌和双歧杆菌属细菌、或含有该2种细菌的发酵乳。
再者,本发明提供用于制造口服用皮肤性状改善剂的链球菌属细菌和双歧杆菌属细菌、或含有该2种细菌的发酵乳的使用。
发明的效果
通过口服摄取本发明的皮肤性状改善剂,显著改善皮肤性状,特别是具有抑制由紫外线照射造成的角质层水分含量的降低或具有角质层水分含量的提高促进作用,改善皮肤的阻挡功能,改善角质层形态(排列规则性、细胞形态清晰性(clarity of cell morphology)等),抑制皮肤的肥厚,抑制皮肤的皱纹形成,抑制经表皮水分蒸散量的增加,具有角质化相关酶活性(组织蛋白酶L样活性)的上升作用等。此外,本发明的皮肤性状改善剂,由于作为有效成分含有能够口服摄取的链球菌属细菌和双歧杆菌属细菌,所以安全性高,能够实现连续的摄取,并且由于该菌的状态不论生死都发挥上述作用效果,所以能够对应于各种嗜好设定摄取时的形态,能够用作口服用医药品、饮料和食品。
附图说明
图1为表示各试验组的体重变化的图。
图2为表示各试验组的摄食量变化的图。
图3为表示各试验组的角质水分量的图。
图4为表示各试验组的经表皮水分蒸散量的图。
图5为表示人在饮用前后的角质水分含量(Corneometer)变化的图。
图6为表示人在饮用前后的角质水分含量(SKICON)变化的图。
图7为表示人角质层细胞的染色图像的图。
图8为表示角质层形态(排列规则性)的得分变化(score shift)的图。
图9为表示角质层形态(细胞形态清晰性)的得分变化的图。
具体实施方式
本发明的口服用皮肤性状改善剂作为有效成分包含链球菌数细菌和双歧杆菌属细菌、或包含含有该2种细菌的发酵乳。
作为本发明中使用的链球菌属细菌可以列举嗜热链球菌(Streptococcus thermophilus,也称为S.therm.)、酿脓链球菌(S.pyogenes)、马链球菌兽瘟亚种(S.zooepidemicus)、马链球菌(S.equi)、停乳链球菌马样亚种(S.equisimilis)、停乳链球菌(S.dysgalactiae)等,从皮肤性状改善效果的观点出发,优选嗜热链球菌。作为嗜热链球菌的具体例子,可以列举嗜热链球菌YIT2021株(FERM BP-7537:保藏日2001年4月5日)、嗜热链球菌YIT2084株(FERM BP-10879:保藏日2007年7月24日)、嗜热链球菌YIT2001(FERM BP-7538:保藏日2001年4月5日)。
作为本发明中使用的双歧杆菌属细菌,可以列举短双歧杆菌(Bifidobacterium breve,也称为B.breve)、长双歧杆菌(B.longum)、两岐双歧杆菌(B.bifidum)、动物双歧杆菌(B.animalis)、猪双歧杆菌(B.suis)、婴儿双歧杆菌(B.infantis)、青春双歧杆菌(B.adolescentis)、链状双歧杆菌(B.catenulatum)、假小链双歧杆菌(B.pseudocatenulatum)、乳双歧杆菌(B.lactis)、球双歧杆菌(B.globosum)等。其中,短双歧杆菌、长双歧杆菌、两岐双歧杆菌以前在乳制品中大量使用,积累有安全性等的数据,而且,从皮肤性状改善效果的观点出发而优选,特别优选短双歧杆菌。作为短双歧杆菌的具体例,可以列举短双歧杆菌YIT12272(FERM BP-11320:保藏日2011年1月20日)、短双歧杆菌YIT4065(FERM BP-6223:保藏日1998年1月16日)。上述的嗜热链球菌和短双歧杆菌保藏于〒305-8566茨城县筑波市东1-1-1筑波中心中央第6国家高级工业科学技术学院国际专利生物保藏中心(AIST)。
上述2种细菌,能够以活菌体原样状态作为皮肤性状改善剂使用,除此之外,能够使用例如活菌体的冻结干燥物、实施了加热处理或醇处理等杀菌处理的死菌体、包含该菌体的培养物或者再加工上述菌体或培养物得到的制品作为皮肤性状改善剂。
本发明的皮肤性状改善剂通过口服摄取,显著改善皮肤的性状,特别是具有抑制由紫外线照射造成的角质层水分含量降低或者具有角质层水分含量的提高促进作用,改善皮肤的阻挡功能,改善角质层形态(排列规则性、细胞形态清晰性等),抑制皮肤的肥厚,抑制皮肤的皱纹形成,抑制经表皮水分蒸散量的增加,具有角质化相关酶活性(组织蛋白酶L样活性)的上升作用等。
本发明中,抑制由紫外线照射造成的角质层水分含量的降低是指例如在通过后述的实施例所示的方法测定角质层水分含量的情况下,抑制由紫外线照射造成的角质层水分含量的降低的作用,另外,角质层水分含量的提高促进作用是指不论紫外线照射的有无,都将角质层水分含量提高促进到与未照射紫外线的健康皮肤同等或者在其以上的水平的作用。其中,作为测定角质层水分含量的方法,不限于后述的实施例所示的方法。
本发明的皮肤性状改善剂中,以提高皮肤性状改善作用为目的,还能够添加难消化性糖类。作为难消化性糖类,优选低聚半乳糖、低聚果糖等的低聚糖,特别优选低聚半乳糖。这些难消化性糖类的每一次的使用量,根据服用的对象的症状、年龄、体重等而不同,因此,不能统一决定,但设为大约0.1~10g左右即可。
本发明的皮肤性状改善剂,能够依照常规方法,与药学上可接受的载体制成各种剂型的医药组合物。
例如,能够在上述菌株或其加工物等中,加入乳糖、白糖、氯化钠、葡萄糖、尿素、淀粉、碳酸钙、高岭土、结晶纤维素、硅酸等的赋形剂,水、乙醇、丙醇、葡萄糖液、淀粉液、明胶溶液、羧甲基纤维素、甲基纤维素、磷酸钾、聚乙烯基吡咯烷酮等的结合剂,藻酸钠、儿茶酸末、碳酸氢钠、碳酸钙、聚氧乙烯脱水山梨糖醇脂肪酸酯类、十二烷基硫酸钠等的崩解剂,甘油、淀粉等的保湿剂,精制滑石、硬脂酸盐、聚乙二醇等的润滑剂等,通过常规方法,制造颗粒剂、片剂、胶囊剂等。并且,对于片剂,根据需要能够制成实施了通常的包衣的片剂,例如糖衣片、明胶包衣片、肠溶包衣片、薄膜包衣片或者双层片、多层片。
本发明的口服用皮肤性状改善剂中,包含链球菌属细菌和双歧杆菌属细菌即可,但是也可以使用含有该2种细菌的发酵乳。作为该发酵乳,只要是在包含乳成分的培养基中培养上述2种细菌得到的发酵乳即可,可以是分别制造在包含乳成分的培养基中培养上述2种细菌的1种的发酵乳、进行混合得到的发酵乳,也可以是在包含乳成分的培养基中混合培养上述2种细菌得到的发酵乳。
作为培养基中包含的乳成分,能够使用牛乳、山羊乳等动物乳、脱脂乳、乳粉、脱脂乳粉、生奶油等。培养根据通常的发酵乳的制造方法即可,例如在25~46℃、优选在35~42℃,进行6~120小时、优选24~72小时即可。培养方法,可以为静置、搅拌、振荡等的任意培养方法。
此外,通过将上述菌体或其加工物等直接添加到食品中,或者在使用乳成分等的可食用性培养基的情况下,通过使用该菌株制造发酵乳等的发酵食品,就能够作为各种饮料和食品利用。作为饮料和食品优选的例子,能够例示酸奶、奶酪、发酵乳、乳制品乳酸菌饮料、发酵豆浆、冰淇淋、果汁饮料、汤、小甜饼干等。
本发明的皮肤性状改善剂,特别是在发酵乳的形态的情况下,能够配合通常使用的各种食品原材料。具体来说,能够列举蔗糖、葡萄糖、果糖、帕拉金糖(Palatinose)、海藻糖、乳糖、木糖、麦芽糖等的糖类,山梨糖醇、木糖醇、赤藓糖醇、乳糖醇、帕拉金糖醇(Plaltinitol)、还原糖浆、还原麦芽糖糖浆等的糖醇,阿斯巴甜、奇异果甜蛋白、三氯蔗糖(Sucralose)、乙酰磺胺酸钾(Acesulfame-K)、甜叶菊(Stevia)等的高甜味度甜味料,琼脂、明胶、角叉菜胶、瓜尔胶、黄原胶、果胶、刺槐豆胶、吉兰糖胶、羧甲基纤维素、大豆多糖类、藻酸丙二醇等的各种增粘稳定剂,蔗糖脂肪酸酯、甘油脂肪酸酯、聚甘油脂肪酸酯、脱水山梨糖醇脂肪酸酯、卵磷脂等的乳化剂,奶油、黄油、酸奶油等的乳脂肪,钙、镁、锌、铁、锰等的矿物成分。
此外,本发明的皮肤性状改善剂,能够配合通过口服摄取对皮肤性状带来有益作用的原材料。作为这样的原材料,能够例示维生素A、维生素B类、维生素C、维生素D、维生素E等的维生素类,β-胡萝卜素、γ-胡萝卜素、叶黄素等的类胡萝卜素,亚油酸、亚麻酸、EPA、DHA等的脂肪酸类,胶原蛋白、粘多糖类、神经酰胺等的皮肤构成成分等。
另外,本发明的皮肤性状改善剂中可以包含能够口服摄取的对生物体赋予有益功能的乳酸菌。
作为这样的乳酸菌,能够例示嗜酸乳杆菌(Lactobacillusacidophilus)、短乳杆菌(Lactobacillus brevis)、棒状乳杆菌(Lactobacilluscoryniformis)、弯曲乳杆菌(Lactobacillus curvatus)、干酪乳杆菌(Lactobacillus casei)、德氏乳杆菌乳亚种(Lactobacillus delbrueckiisubsp.lactis)、德氏乳杆菌保加利亚亚种(Lactobacillus delbrueckii subsp.bulgaricus)、发酵乳杆菌(Lactobacillu fermentum)、鸡乳杆菌(Lactobacillus gallinarum)、加氏乳杆菌(Lactobacillus gasseri)、瑞士乳杆菌(Lactobacillus helveticus)、约氏乳杆菌(Lactobacillus johnsonii)、高加索酸奶乳杆菌(Lactobacillus kefiri)、苹果乳杆菌(Lactobacillusmali)、植物乳杆菌(Lactobacillus plantarum)、戊糖乳杆菌(Lactobacilluspentosus)、类干酪乳杆菌(Lactobacillus paracasei)、清酒乳杆菌(Lactobacillus sakei)、玉米乳杆菌(Lactobacillus zeae)等的乳杆菌属细菌,乳酸乳球菌乳亚种(Lactococcus lactis subsp.lactis)、乳酸乳球菌乳脂亚种(Lactococcus lactis subsp.cremoris)、植物乳球菌(Lactococcus plantarum)等的乳球菌属细菌,肠膜明串珠菌乳脂亚种(Leuconostocmesenteroides subsp.cremoris)、乳明串珠菌(Leuconostoclactis)等的明串珠菌属细菌,乳酸片球菌(Pediococcus acidilactici)、戊糖片球菌(Pediococcus pentosaceus)、嗜盐片球菌(Pediococcushalophilus)等的片球菌属细菌,屎肠球菌(Enterococcus faecium)、屎肠球菌(Enterococcus faecalis)等的肠球菌属细菌。它们可以单独也可以并用2种以上。
本发明的能够口服摄取的皮肤性状改善剂中链球菌属细菌和双歧杆菌属细菌的每一次的使用量,根据服用的对象的症状、年龄、体重等不同,因此不能统一决定,但是作为大约菌数分别设为103~1013CFU左右即可,特别是优选分别设为106~1013CFU左右。
此外,本发明的皮肤性状改善剂的摄取开始时间和摄取期间等没有特别限定,只要在伴随着紫外线照射的皮肤问题发生前后口服摄取即可,但为了得到充分的效果,不管有无伴随着紫外线的照射的皮肤问题的产生等,优选连续地口服摄取。
实施例
以下,列举实施例更详细地说明本发明,但是本发明不受这些实施例任何限定。
参考例1
通过交替传代培养的短双歧杆菌YIT 10001、YIT 4125的育种改良
短双歧杆菌YIT 10001株(FERM BP-8205)和短双歧杆菌YIT 4125(FERM BP-7813)作为亲株,进行交替传代浓缩。
(1)将20.7%的全脂乳粉培养基在135℃杀菌3.5秒,之后,接种0.5%的短双歧杆菌YIT 10001株或YIT 4125株的子菌种1(seedstarter)、1%的两岐双歧杆菌的子菌种,在33℃混合培养到pH5.3,调制菌液A1(400mL)。
(2)向菌液A1中配合糖浆液A,使得帕拉金糖的最终浓度为10%,调制乳制品A1(630mL)。将乳制品A1(200mL)分注入300mL的烧瓶中,塞好棉栓,在这样的需氧条件下,在5℃进行1周(90rpm)搅拌保存(以后,简称为需氧搅拌保存),然后,在试管中填充满管,在塞入丁基橡胶塞的厌氧条件下,在10℃,静置保存一周(以后,简称为厌氧静置保存)。
(3)将在本条件保存的乳制品A1(1mL)接种在添加有头孢菌素的奶培养基(12%脱脂乳粉、0.1%酵母提取物、0.03%L-半胱氨酸盐酸盐、0.2%沉淀性碳酸钙、头孢菌素5μg/mL,以后,简称为添加有头孢菌素的奶培养基)10mL中,在37℃,24小时厌氧培养,得到短双歧杆菌的母菌种(mother starter)2。将母菌种2(0.03mL)接种在奶培养基(12%脱脂乳粉、0.1%酵母提取物、0.03%L-半胱氨酸盐酸盐、0.2%沉淀性碳酸钙,以后,称为奶培养基)30mL中,在37℃、厌氧培养24小时,调制短双歧杆菌的子菌种2。使用子菌种2重复进行与上述同样的操作。即,将子菌种2调制的乳制品A2进行需氧搅拌保存后,进行厌氧静置保存,调制短双歧杆菌的母菌种3、以及子菌种3。
(4)接着,将23.5%脱脂乳粉培养基在120℃杀菌3.5秒之后,接种2%的短双歧杆菌的子菌种3、0.01%的乳酸乳球菌的子菌种,在37℃混合培养到pH4.4,调制菌液B1(100mL)。
(5)此外,在120℃、3.5秒杀菌后的19.7%脱脂乳粉培养基中添加0.08%乳肽,之后,接种0.5%嗜热链球菌的子菌种,在37℃培养到pH4.3,调制菌液C1(700mL)。向菌液B1中加入菌液C1(混合比1:2),配合糖浆液B使得还原麦芽糖糖浆的最终浓度为5%,调制乳制品B1(870mL)。
(6)与乳制品A1同样,在添加有头孢菌素的奶培养基10mL中接种需氧搅拌保存后厌氧静置保存的乳制品B1(1mL),在37℃进行24小时厌氧培养,得到短双歧杆菌的母菌种4。在奶培养基30mL中接种母菌种4(0.03mL),在37℃进行厌氧培养24小时,调制短双歧杆菌的子菌种4。使用子菌种4,重复与上述同样的操作。即,将由子菌种4调制的乳制品B2需氧搅拌保存后进行厌氧静置保存,调制短双歧杆菌的母菌种5、以及子菌种5。
如此,重复2次乳制品A的调制、需氧搅拌保存和厌氧静置保存,之后,使用存活的短双歧杆菌,重复2次乳制品B的调制、需氧搅拌保存和厌氧静置保存,进行短双歧杆菌的浓缩操作。这一系列工序为1个循环,合计重复4个循环。最终,从10℃、厌氧静置保存2周的乳制品A8和乳制品B8中,各取出1mL涂布在添加有5μg/mL头孢菌素的TOS丙酸琼脂培养基(Yakult药品工业)中,在37℃以Anaero Pack(三菱气体化学)进行厌氧培养,分离菌落。通过反复进行该菌落分离,进行纯化,将来自短双歧杆菌YIT 10001株和YIT 4125株的单菌落从乳制品A8中分离合计21株,从乳制品B8中分离合计21株,合计分离42株。
参考例2
存活性确认试验
使用亲株和分离株,用参考例1的方法,分别调制乳制品A、B,在需氧条件下、5℃、搅拌保存1周之后,在厌氧条件下、10℃、静置保存2周。筛选在乳制品A、B两者中存活性良好的短双歧杆菌YIT12272株(来自YIT 4125株,由乳制品A8分离)。
YIT12272株,对照菌(YIT 10001株、YIT 4125株)在乳制品A、B中的存活性的结果示于表1。YIT12272株在乳制品A、B的任一个中,即使在需氧条件下、5℃、搅拌保存1周后,在厌氧条件下、10℃、静置保存2周,都存活3×107cfu/mL以上的活菌。另一方面,虽然由对照菌制备的乳制品A、B的任一个中,都存活有3×107cfu/mL以上的活菌,但是在两个制品中都没有显示良好的存活性。
此外,乳制品A、B的物性示于表2。在菌液A中配合糖浆A,调制乳制品A,乳制品A的pH、酸度分别为5.6、3.4,菌液A的渗透压为550mOsm,乳制品A增加至950mOsm。另一方面。在菌液B中配合菌液C和糖浆B,调制乳制品B,乳制品B的pH、酸度分别为4.4、7.5,菌液B的渗透压为900mOsm,乳制品B减少至600mOsm。
由以上可知,短双歧杆菌YIT12272株在培养温度、pH、酸度、配合糖浆引起的渗透压变化、无脂乳固体成分、乳脂肪成分不同的乳制品A、B中,与对照菌相比,存活性得到强化。
[表1]
乳制品A、B保存后的短双歧杆菌YIT12272株的活菌数
需氧条件下、5℃、搅拌保存1周后,厌氧条件下、10℃、静置保存2周,在添加有5μg/mL头孢菌素的TOS丙酸琼脂培养基中测定活菌数
[表2]
乳制品A、B的物性
渗透压:由京都第一科学株式会社制造的Osmostart OM-6040测定
实施例1
(1)实验动物和饲养方法
使用5周龄的雌性无毛小鼠(Hos:HR-1)。在CS笼中群养,使用AIN93G饲料驯化1周,之后,以没有体重差别的方式分组,使用试验食品饲养2周。饲养条件在实验期间设为恒温(24±1℃)、恒湿(60±5%),明暗周期为12小时。饲料和水使其自由摄取。改良AIN93N的组成制作饲料。饲料在乳钵中混合后加入适量去离子水,制成膏状,移动到冻结干燥托盘中,切割为块状。冻结干燥后,真空包装进行冷藏保存。饲料组成如表3所示。
[表3]
(2)实验组
[表4]
B.breve:短双歧杆菌YIT12272
S.therm.:嗜热链球菌YIT2084
(3)试验饲料
(a)B.breve.菌末…通过常规方法调制m-ILS液体培养基,在121℃进行15分钟灭菌处理,在气相N2置换条件下,接种1%子菌种,在37℃培养23小时。培养结束后的活菌数为1.16×109CFU/mL。该培养液通过生理食盐水清洗,除去培养基成分,混合到改良AIN-93G饲料中。混合后冻结干燥,制作固体饲料。
(b)B.breve.发酵乳…调制在10%脱脂乳粉(YOTSUBA YAA)中加入有0.03%Yeast Extract的培养基,在121℃灭菌处理15分钟,在气相N2置换条件下接种1%的依照常规方法调制的子菌种,在37℃培养44小时。培养结束后的活菌数为1.02×108CFU/mL。将该培养液冻结干燥、粉末化后,混合到饲料中。混合后,进行冻结干燥,制作固体饲料。
(c)S.therm.发酵乳…在10%脱脂乳粉中接种0.1%子菌种,加入另外灭菌的Hinute DH(不二制油),通过发酵罐(B.E.MARUBISHI)在37℃、100rpm、pH6.8培养24小时。培养结束后的活菌数为5×108CFU/mL。将该培养液冻结干燥、粉末化后,混合到饲料中。混合后,进行冻结干燥,制作固体饲料。
(d)B.breve.+S.therm.混合发酵乳…以上述方法培养,分别添加粉末化的B.breve.发酵乳和S.therm.发酵乳粉末10%,制作饲料。
(4)菌数测定方法
通过0.1%Bacto yeast extract(Difco公司生产)适当稀释在乳钵中匀浆化的饵料,涂布在琼脂平板培养基中,测定活菌数。
(5)实验日程
从摄取试验食物的第11日开始通过紫外线照射装置(东芝SE-FL-20),以40mJ/cm2/day进行4日的紫外线照射,次日解剖。体重测定一周一次,摄食量测定一周进行2~3次左右,此外进行日常观察。
(6)测定项目
从试验食物开始第15日,使用皮肤计测仪器,测定皮肤性状。
(a)经表皮水分蒸散量(TEWL)
使用Tewa meter TM210(Courage+khazaka electronic GmbH)测定经表皮水分蒸散量,作为生物功能的指标。数值每2秒测定,计算并表示出30秒的平均值。
(b)角质层水分含量
使用3.5MHZ的高频电导率测定装置(SKICON-200,IBS),测定小鼠背部皮肤角质层的电导率值。
(7)统计
统计处理使用SAS的前临床程序包,显著差别检验进行Dunnett检验。
(8)
a.体重和摄食量
体重和摄食量的经时变化如图1和图2所示。任意组之间没有显著差别,没有发现紫外线照射或者样品差异造成的小鼠的生长和健康状况的差异。
(b)皮肤性状
b-1角质层水分含量
角质层水分含量如图3所示。角质层水分含量通过紫外线照射显著降低,但是在短双歧杆菌和嗜热链球菌混合发酵乳组中抑制了显著降低。其结果,与分别单独投放短双歧杆菌或嗜热链球菌的组相比,具有协同效果。其值甚至高于没有照射紫外线的空白组,显示极为显著的效果。即,本发明的皮肤性状改善剂,不仅能够单纯抑制紫外线照射带来的角质层水分含量降低,还具有将角质层水分含量提高促进到与未照射紫外线的健康皮肤同等或以上水平的作用,显示极高的实用性。
b-2经表皮水分蒸散量(TEWL)
TEWL示于图4。通过紫外线照射,TEWL显著提升,表明表皮阻挡功能下降。所有组中都有显著改善,该改善效果在短双歧杆菌和嗜热链球菌混合发酵乳组中最高。
实施例2
(1)含有短双歧杆菌YIT12272和嗜热链球菌YIT2021的发酵乳的制造
在120℃进行了3.5秒平皿杀菌的脱脂乳粉溶液(SNF20.7%)中接种2%短双歧杆菌YIT12272的前培养液,在37℃培养24小时,得到双歧杆菌发酵乳。同样,在平皿杀菌过的脱脂乳粉溶液(SNF17.4%)中接种0.5%的嗜热链球菌YIT2021的前培养液,在37℃培养24小时,得到乳酸菌发酵乳。混合这些菌液,加入配合有还原麦芽糖糖浆、聚糊精、低聚半乳糖、乳化铁、阿斯巴甜等的糖浆溶液,得到发酵乳。
作为安慰剂,制造不含上述细菌和低聚半乳糖的未发酵乳。未发酵乳中添加与上述发酵乳所含的量等量的乳酸和乙酸。
各饮料的成分组成如表5所示。试验饮料的饮用开始后的YIT12272的平均活菌数和平均总乳酸菌数分别为6.9×108CFU/mL、5.1×108CFU/mL。此外,饮用结束时的YIT12272的平均活菌数和平均总乳酸菌数分别为6.6×108CFU/mL、5.1×108CFU/mL。
[表5]
(2)对于安慰组和试验组各20名(女性)4周每天使其各饮用1支(100mL)。评价饮用前、饮用后和后观察后(饮用结束2周后)的皮肤性状。
对于皮肤测量,通过由洗面奶洗脸,去掉化妆品,在30分钟放松状态下驯化肌肤,之后,以仰着的状态躺在床上,将左脸(眼角和鼻的交点)的角质层水分含量使用Corneometer(商标)CM825(株式会社Integral制造)和SKICON-200(IBS公司制造)测定5次计算平均值。此外,左脸的水分蒸散量使用Cutometer MPA 580(商标)(株式会社Integral制造)测定。
对于皱纹测量,从被测试者的左眼角使用有机硅橡胶(SILFLO,Flexico Developments)制作阴模复制品,通过数字显微镜获取该复制品的图像后,进行图像分析(WinROOF Pro Ver.6.1:三谷商事)。皱纹依照日本化妆品工业联合会制作的皱纹测量法的指南进行解析,作为测量数据,以皱纹最大深度(mm)表示。
作为肌肤的更新(turnover)的正常化指标,测定作为角质化相关酶的组织蛋白酶L样活性。方法按照常规方法,使用作为合成肽的Z-Val-Val-Arg-MCA为基质进行荧光分析。
对于角质层采取,饮用前和后观察后选取相同部位,饮用后选取与饮用前不同的部位,分别通过胶带剥离方法在同一部位采取3层。将角质层第二层的采取样品在0.5%亮绿-1.0%龙胆紫B水溶液中、室温、8分钟染色,之后,用蒸馏水清洗。通过数字显微镜获取该图像后,使用上述图像分析装置,进行角质细胞面积、圆形度和周长的测定。对每1名被测试者从3个视野测定30个角质细胞面积。此外,角质层形态(排列规则性和细胞形态清晰性)根据分别表示在表6和表7中的评价基准进行得分化,将3名观察者的得分平均。
[表6]
排列规则性的评价基准
得分 | 基准 |
1 | 几乎没有具有规则性的集落(colony) |
2 | 不规则集落多 |
3 | 具有规则性的集落多 |
4 | 几乎都为规则性集落 |
[表7]
细胞形态清晰性评价基准
得分 | 基准 |
1 | 几乎都为轮廓不清晰的细胞 |
2 | 轮廓不清晰的细胞多 |
3 | 轮廓清晰的细胞多 |
4 | 几乎都为轮廓清晰的细胞 |
(3)结果
3-1角质层水分含量
角质层水分含量的变化如图5~6所示。通过SKICON测定的结果,安慰组在饮用后、后观察后与饮用前相比显著降低。另一方面,试验组在饮用后没有变化,在后观察后显著降低。通过CORNEOMETER测定的结果,安慰组中在饮用后、后观察后都确认到显著降低,但试验组与饮用前相比没有变化。试验组与安慰组的比较中,尽管试验组在饮用后、后观察后没有显著差异,但显示高的值。
3-2角质化相关酶
试验组中,组织蛋白酶L样活性,与饮用前相比,在饮用后显著上升。另一方面,安慰群中没有看到变化。
3-3角质层形态
研究角质层细胞面积、周长和圆形度(4π×面积/(周长)2、0<圆形度≤1)的变化。角质层细胞的形态,形状越大,越接近圆形(正六边形)越为良好的状态,因此任一个测定项目的值越大则角质层的状态判定为越好。圆形度在两组中,与饮用前相比,在饮用后、后观察后都显著上升。作为一例,试验组的50多岁的女性的角质层细胞的染色图像如图7所示。观察到饮用前细胞小形状也不均一,而饮用后,细胞变大,处于形状整齐(正六边形)的状态。
将角质层形态(排列规则性和细胞形态清晰性)以分值化评价的结果(得分值利用与饮用前的变化量(Δ得分)表示)示于图8和图9。与安慰组相比,试验组中在饮用后的得分改善效果高,还确认到存在饮用的改善效果在后观察后持续的倾向。
3-4皱纹
皱纹最大深度,在安慰组中没有变化,但在试验组中,与饮用前相比显著减少。
实施例3
含有短双歧杆菌YIT4065和嗜热链球菌YIT2021的发酵乳的制造
在120℃进行了3.5秒平皿杀菌的脱脂乳粉溶液(SNF20.7%)中接种2%短双歧杆菌YIT4065的前培养液,在37℃培养24小时,得到双歧杆菌发酵乳。同样,在平皿杀菌的脱脂乳粉溶液(SNF17.4%)中接种0.5%的嗜热链球菌YIT2021的前培养液,在37℃培养24小时,得到乳酸菌发酵乳。混合这些菌液,加入配合有还原麦芽糖糖浆、聚糊精、低聚半乳糖、乳化铁、阿斯巴甜等的糖浆溶液,得到发酵乳。
确认了短双歧杆菌YIT4065通过口服摄取的皮肤性状改善作用(TEWL、水分含量、皮沟、皮丘数目等)与短双歧杆菌YIT12272具有同等效果,本实施例的发酵乳能够期待具有本发明的皮肤性状改善作用。
实施例4
含有短双歧杆菌YIT4065和嗜热链球菌YIT2084的发酵乳的制造
在120℃进行了3.5秒平皿杀菌的脱脂乳粉溶液(SNF20.7%)中接种2%短双歧杆菌YIT4065的前培养液,在37℃培养24小时,得到双歧杆菌发酵乳。同样,在平皿杀菌的脱脂乳粉溶液(SNF17.4%)中接种0.5%的嗜热链球菌YIT2084的前培养液,在37℃培养24小时,得到乳酸菌发酵乳。混合这些菌液,加入配合有还原麦芽糖糖浆、聚糊精、低聚半乳糖、乳化铁、阿斯巴甜等的糖浆溶液,得到发酵乳。
确认了短双歧杆菌YIT4065通过口服摄取的皮肤性状改善作用(TEWL、水分含量、皮沟、皮丘数目等)与短双歧杆菌YIT12272具有同等效果,本实施例的发酵乳能够期待具有本申请发明的皮肤性状改善作用。
Claims (24)
1.一种口服用皮肤性状改善剂,其特征在于,以链球菌属细菌和双歧杆菌属细菌、或含有该2种细菌的发酵乳作为有效成分。
2.如权利要求1所述的口服用皮肤性状改善剂,其特征在于,链球菌属细菌为嗜热链球菌。
3.如权利要求1或2所述的口服用皮肤性状改善剂,其特征在于,链球菌属细菌为嗜热链球菌YIT2021株(FERM BP-7537)或嗜热链球菌YIT2084株(FERM BP-10879)。
4.如权利要求1~3中任一项所述的口服用皮肤性状改善剂,其特征在于,双歧杆菌属细菌为短双歧杆菌。
5.如权利要求1~4中任一项所述的口服用皮肤性状改善剂,其特征在于,双歧杆菌属细菌为短双歧杆菌YIT4065株(FERM BP-6223)或短双歧杆菌YIT12272株(FERM BP-11320)。
6.如权利要求1~5中任一项所述的口服用皮肤性状改善剂,其特征在于,还含有低聚半乳糖。
7.如权利要求1~6中任一项所述的口服用皮肤性状改善剂,其特征在于,皮肤性状改善为抑制紫外线照射造成的角质层水分含量的降低。
8.如权利要求1~7中任一项所述的口服用皮肤性状改善剂,其特征在于,皮肤性状改善为促进角质层水分含量的上升。
9.口服摄取、改善皮肤性状用的链球菌属细菌和双歧杆菌属细菌的组合、或含有该2种细菌的发酵乳。
10.如权利要求9所述的组合或发酵乳,其特征在于,链球菌属细菌为嗜热链球菌。
11.如权利要求9或10所述的组合或发酵乳,其特征在于,链球菌属细菌为嗜热链球菌YIT2021株(FERM BP-7537)或嗜热链球菌YIT2084株(FERM BP-10879)。
12.如权利要求9~11中任一项所述的组合或发酵乳,其特征在于,双歧杆菌属细菌为短双歧杆菌。
13.如权利要求9~12中任一项所述的组合或发酵乳,其特征在于,双歧杆菌属细菌为短双歧杆菌YIT4065株(FERM BP-6223)或短双歧杆菌YIT12272株(FERM BP-11320)。
14.如权利要求9~13中任一项所述的组合或发酵乳,其特征在于,还含有低聚半乳糖。
15.如权利要求9~14中任一项所述的组合或发酵乳,其特征在于,皮肤性状改善为抑制紫外线照射造成的角质层水分含量的降低。
16.如权利要求9~15中任一项所述的组合或发酵乳,其特征在于,皮肤性状改善为促进角质层水分含量的上升。
17.一种皮肤性状改善方法,其特征在于,口服摄取链球菌属细菌和双歧杆菌属细菌、或含有该2种细菌的发酵乳。
18.如权利要求17所述的方法,其特征在于,链球菌属细菌为嗜热链球菌。
19.如权利要求17或18所述的方法,其特征在于,链球菌属细菌为嗜热链球菌YIT2021株(FERM BP-7537)或嗜热链球菌YIT2084株(FERM BP-10879)。
20.如权利要求17~19中任一项所述的方法,其特征在于,双歧杆菌属细菌为短双歧杆菌。
21.如权利要求17~20中任一项所述的方法,其特征在于,双歧杆菌属细菌为短双歧杆菌YIT4065株(FERM BP-6223)或短双歧杆菌YIT12272株(FERM BP-11320)。
22.如权利要求17~21中任一项所述的方法,其特征在于,还口服摄取低聚半乳糖。
23.如权利要求17~22中任一项所述的方法,其特征在于,皮肤性状改善为抑制紫外线照射造成的角质层水分含量的降低。
24.如权利要求17~23中任一项所述的方法,其特征在于,皮肤性状改善为促进角质层水分含量的上升。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-145766 | 2010-06-28 | ||
JP2010145766 | 2010-06-28 | ||
PCT/JP2011/064681 WO2012002322A1 (ja) | 2010-06-28 | 2011-06-27 | 経口用皮膚性状改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103249420A true CN103249420A (zh) | 2013-08-14 |
CN103249420B CN103249420B (zh) | 2016-06-29 |
Family
ID=45402034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180031742.5A Active CN103249420B (zh) | 2010-06-28 | 2011-06-27 | 口服用皮肤性状改善剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9439933B2 (zh) |
EP (1) | EP2586448B1 (zh) |
JP (1) | JP5903380B2 (zh) |
KR (1) | KR101757504B1 (zh) |
CN (1) | CN103249420B (zh) |
WO (1) | WO2012002322A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110179835A (zh) * | 2014-05-12 | 2019-08-30 | 美国宝微技术股份有限公司 | 改善人类皮肤健康的组合物及其在制备产品中的用途 |
TWI764295B (zh) * | 2019-09-24 | 2022-05-11 | 大江生醫股份有限公司 | 加氏乳桿菌tci943或其代謝產物及其用於改善肌膚狀況的用途 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108771687A (zh) | 2012-02-29 | 2018-11-09 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
KR102355751B1 (ko) * | 2013-07-05 | 2022-01-26 | 가부시키가이샤 야쿠르트 혼샤 | 펜토시딘 생성 저해제 |
JP6090854B2 (ja) * | 2013-11-15 | 2017-03-08 | 株式会社東洋新薬 | コラーゲン産生促進用組成物 |
CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
WO2017057319A1 (ja) * | 2015-09-30 | 2017-04-06 | 株式会社明治 | 乳酸菌スターターの調製方法及び発酵乳の製造方法 |
SG10201912918TA (en) * | 2016-03-24 | 2020-02-27 | Meiji Co Ltd | Composition for inhibiting erythema formation, method of using same, method for preparing same, method for inhibiting erythema, and lactic acid bacteria producing substance |
WO2019019961A1 (zh) * | 2017-07-26 | 2019-01-31 | 海思科医药集团股份有限公司 | 防治消化道和/或皮肤反应的菌群及其应用 |
CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
JP6846376B2 (ja) | 2018-03-15 | 2021-03-24 | キリンホールディングス株式会社 | 皮膚状態改善用組成物 |
KR102615130B1 (ko) * | 2018-09-21 | 2023-12-19 | 주식회사 팜스킨 | 초유의 발효산물의 항아토피용 조성물 |
SG11202108657YA (en) * | 2019-02-19 | 2021-09-29 | Yakult Honsha Kk | Method for producing culture of lactic acid bacterium and/or bacterium belonging to genus bifidobacterium |
KR102236944B1 (ko) * | 2020-04-29 | 2021-04-06 | (주)네오크레마 | 갈락토올리고당, 또는 갈락토올리고당 및 콜라겐 트리펩타이드를 포함하는 면역기능 개선 및 피부상태 개선용 기능성 식품조성물 및 화장료 조성물 |
GB202215592D0 (en) * | 2022-10-21 | 2022-12-07 | Iiaa Ltd | Cosmetic compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133921A1 (en) * | 2000-05-16 | 2003-07-17 | Kenji Ohishi | Adsorbent for endocrine disruptors and foods and drinks containing the same |
JP2009114080A (ja) * | 2007-11-02 | 2009-05-28 | Icreo Co Ltd | アトピー性皮膚炎治療組成物 |
CN101505721A (zh) * | 2006-08-30 | 2009-08-12 | 株式会社益力多本社 | 皱纹形成抑制剂 |
JP2010006757A (ja) * | 2008-06-27 | 2010-01-14 | Yakult Honsha Co Ltd | 経口摂取用皮膚性状改善剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07265064A (ja) * | 1993-11-23 | 1995-10-17 | Taketoshi Yamada | 腸内細菌叢改善組成物 |
EP0856259B1 (en) * | 1996-12-23 | 1998-08-12 | SITIA-YOMO S.p.A. | Composition for feed use comprising lyophilized live lactic bacteria |
JP2001252048A (ja) | 2000-03-14 | 2001-09-18 | Fancl Corp | 食品組成物 |
US7794763B2 (en) | 2001-11-05 | 2010-09-14 | Kabushiki Kaisha Yakult Honsha | Bacterium of the genus bifidobacterium and fermented foods using the same |
JP2005526038A (ja) * | 2002-02-21 | 2005-09-02 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 皮膚の光防護のための経口投与可能な組成物 |
DE60317646T2 (de) | 2002-02-21 | 2008-10-30 | Société des Produits Nestlé S.A. | Photoprotektive oral verabreichbare zusammensetzung für die haut |
JP2004039423A (ja) * | 2002-07-03 | 2004-02-05 | Matsushita Electric Ind Co Ltd | 環形蛍光ランプ |
JP5048246B2 (ja) | 2003-08-26 | 2012-10-17 | 日本ケフィア株式会社 | スキンケア用の内服組成物 |
JP4680571B2 (ja) | 2003-12-25 | 2011-05-11 | カルピス株式会社 | 経口摂取用保湿剤 |
JP2008503563A (ja) * | 2004-06-23 | 2008-02-07 | ロレアル | 敏感及び/又は乾燥肌の予防及び/又は処置に有用な方法及び組成物 |
JP5635221B2 (ja) * | 2004-12-24 | 2014-12-03 | 株式会社明治 | 皮膚改善用及び/又は治療用の発酵乳とその製造方法 |
US20110097437A1 (en) * | 2008-06-13 | 2011-04-28 | N.V. Nutricia | Nutrition for prevention of infections |
-
2011
- 2011-06-27 KR KR1020127033087A patent/KR101757504B1/ko active IP Right Grant
- 2011-06-27 JP JP2012522620A patent/JP5903380B2/ja active Active
- 2011-06-27 US US13/805,908 patent/US9439933B2/en active Active
- 2011-06-27 EP EP11800786.3A patent/EP2586448B1/en active Active
- 2011-06-27 CN CN201180031742.5A patent/CN103249420B/zh active Active
- 2011-06-27 WO PCT/JP2011/064681 patent/WO2012002322A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133921A1 (en) * | 2000-05-16 | 2003-07-17 | Kenji Ohishi | Adsorbent for endocrine disruptors and foods and drinks containing the same |
CN101505721A (zh) * | 2006-08-30 | 2009-08-12 | 株式会社益力多本社 | 皱纹形成抑制剂 |
JP2009114080A (ja) * | 2007-11-02 | 2009-05-28 | Icreo Co Ltd | アトピー性皮膚炎治療組成物 |
JP2010006757A (ja) * | 2008-06-27 | 2010-01-14 | Yakult Honsha Co Ltd | 経口摂取用皮膚性状改善剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110179835A (zh) * | 2014-05-12 | 2019-08-30 | 美国宝微技术股份有限公司 | 改善人类皮肤健康的组合物及其在制备产品中的用途 |
TWI764295B (zh) * | 2019-09-24 | 2022-05-11 | 大江生醫股份有限公司 | 加氏乳桿菌tci943或其代謝產物及其用於改善肌膚狀況的用途 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2012002322A1 (ja) | 2013-08-22 |
EP2586448A4 (en) | 2014-01-15 |
CN103249420B (zh) | 2016-06-29 |
US20130095073A1 (en) | 2013-04-18 |
WO2012002322A1 (ja) | 2012-01-05 |
EP2586448A1 (en) | 2013-05-01 |
KR20130119849A (ko) | 2013-11-01 |
US9439933B2 (en) | 2016-09-13 |
JP5903380B2 (ja) | 2016-04-13 |
EP2586448B1 (en) | 2018-02-07 |
KR101757504B1 (ko) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103249420B (zh) | 口服用皮肤性状改善剂 | |
JP5791009B2 (ja) | 乳酸菌およびそれらを用いた飲食物又は化粧品 | |
JP5954828B2 (ja) | 皮膚状態の改善用組成物 | |
US20110038837A1 (en) | Composition for improving intestinal microflora | |
CN105497078A (zh) | 新颖的鼠李糖乳杆菌菌株及其用于抑制黄嘌呤氧化酶及治疗痛风的代谢产物 | |
CN103607997B (zh) | 用于预防和/或治疗头皮的头皮屑病症的有益活性剂 | |
KR20160130779A (ko) | 수면의 질 개선제 | |
JP5046684B2 (ja) | 腸管バリア機能の機能回復剤及び腸管バリア透過性の亢進阻害剤 | |
KR20060135016A (ko) | 유카 추출물, 퀼라야 추출물 및 유산균을 포함하는 조성물및 상기 조성물을 함유하는 음식물 | |
CN102762194A (zh) | 益生菌微生物作为抵抗皮肤纹理变化的活性剂 | |
JPWO2018155660A1 (ja) | 乳酸菌の死菌体又はその処理物を含有する組成物並びに該組成物を含む化粧品、生活用品、薬剤又は食品 | |
CN104432001A (zh) | 可食用组合物及其用途 | |
JPWO2018003900A1 (ja) | 栄養状態改善に使用するための組成物 | |
JP5254682B2 (ja) | 経口摂取用皮膚性状改善剤 | |
CN104771416A (zh) | 用于控制体重的罗伊氏乳杆菌gmnl-263组合物及其用途 | |
CN106890198A (zh) | 癌症发病风险降低剂 | |
JP5048246B2 (ja) | スキンケア用の内服組成物 | |
CN110025501A (zh) | 用于皮肤补充水分的组合物及其制备方法和应用 | |
JP6061530B2 (ja) | Nash予防治療剤 | |
JP5413819B2 (ja) | 肝機能改善剤およびその製造用ツール、ならびにこれらの利用 | |
Ma et al. | Effects of different sugars, alcohols, antioxidants on goat milk tablets containing Lactobacillus acidophilus LA-5 | |
CN108991115A (zh) | 一种发酵型合生元羊奶片及其制备方法 | |
Aluko et al. | Physico-chemical, microbiological and sensory qualities of probotic yoghurt enriched with baobab pulp. | |
Chavda et al. | A Glance to the Patent World of Probiotics 15 | |
CN104023546A (zh) | 扁平上皮癌预防剂、以及扁平上皮癌模型动物及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |